Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.48 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14252289 | 1.00 | MAPK1 (0.49) | MAPK1LGALS3LGALS8LGALS4L3MBTL1 | |
| SCHEMBL28235038 | 1.00 | MAPK1 (0.49) | MAPK1LGALS3LGALS8LGALS4L3MBTL1 | |
| SCHEMBL12908201 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL28862276 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL28156231 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL23545823 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL19498843 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL30231904 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL927214 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL28156223 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527733-B2 | Fragrance compositions | ELC MANAGEMENT LLC (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3103523-B1 | ABSORBENT ARTICLE COMPRISING FRAGRANCE COMPOSITION | PROCTER & GAMBLE (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4384137-A1 | FRAGRANCE COMPOSITIONS | ELC Management LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-117940102-A | Fragrance composition | ELC管理有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-3141239-B1 | FRAGRANCE COMPOSITIONS AND USES THEREOF | PROCTER & GAMBLE (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230048533-A1 | FRAGRANCE COMPOSITIONS | ELC MANAGEMENT LLC | 2023-02-16 | — | — | US | disclosed |
| WO-2023018673-A1 | FRAGRANCE COMPOSITIONS | ELC MANAGEMENT LLC (US) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527733-B2 | Fragrance compositions | CUTA, IL36G, TAS2R40 | MAPK1 3588/4885LGALS3 3358/4885LGALS8 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.